Amgen to terminate participation in co-development and commercialization of brodalumab
Research and Markets: Global Anal Cancer Pipeline Report 2015 - 6 Companies & 6 Drug Profiles
Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients
Immune Pharmaceuticals and STC Biologics announce strategic partnership to accelerate the development of NanomAbs®
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Three ways to separate long-term winners from stocks that fizzle.
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...